or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission file number: 001-37761 VistaGen Therapeutics, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended: March 31, 2019 (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Nevada 20-5093315 343 Aller ...

VistaGen® | --- | --- | --- | --- | --- | |-------|----------------------------------------------|-------|-------|------------------| | | | | | | | | | | | | | | LOOKING BEYOND CURRENT | | | | | | | | | | | | TREATMENTS FOR | | | | | | CENTRAL NERVOUS SYSTEM (CNS) | | | | | | DISEASES AND DISORDERS WITH HIGH UNMET NEED | | | www.vistagen.com | | | :VTGN | | | Spring 2019 | vistagen.co m www.vistagen.comForward-looking www.Statements This presentation contains "forward-looking statements" within the meaning ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-37761 VistaGen Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of inc ...